CML
Showing 1 - 25 of 25
Venetoclax Tablets Crushed and Dissolved Into a Solution
Not yet recruiting
- Hematologic Malignancy
- +18 more
- 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
-
Cincinnati, OhioCincinnati Children's Hospital Medical Center
Nov 8, 2023
AML, ALL, Lymphoid Malignancies Trial in Birmingham (Infusion of CD34 selected hematopoietic stem cells)
Not yet recruiting
- AML
- +5 more
- Infusion of CD34 selected hematopoietic stem cells
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Sep 14, 2023
CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)
Recruiting
- CML
- Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
-
Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, ArgentinaFUNDALEU
Jun 29, 2023
CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic Trial in Worldwide (Asciminib add-on, Imatinib, Nilotinib)
Recruiting
- CML
- +3 more
- Asciminib add-on
- +3 more
-
Augusta, Georgia
- +46 more
Jan 23, 2023
Outcomes of Tyrosine Kinase Inhibitor(TKI)Stopping in Chronic
Recruiting
- Folate
- +2 more
-
Nantong, ChinaAffliated Hospital of Nantong University
Dec 13, 2021
CML, Imatinib Trial in Seoul (high-dose imatinib)
Completed
- CML
- Imatinib
- high-dose imatinib
-
Seoul, Korea, Republic ofNovartis Investigational Site
Mar 9, 2021
Care Needs in CML and GIST Receiving Oral Targeted Therapy
Completed
- CML
- GIST
-
Taipei, TaiwanNational Taiwan University Hosptial
Aug 7, 2020
CML Trial in Brussels (200 Mg capsules of bosutinib in Water solution, bosunitib sorbitol, Bosutinib Mannitol)
Completed
- CML
- 200 Mg capsules of bosutinib in Water solution
- +13 more
-
Brussels, BelgiumPfizer Clinical Research Unit
Jul 8, 2020
ALL, Burkitt's Lymphoma, Lymphoblastic Leukemia Trial in Philadelphia (Rapamycin + high dose etoposide and cytarabine)
Terminated
- ALL
- +3 more
- Rapamycin + high dose etoposide and cytarabine
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania Abramson Cancer Center
Apr 15, 2020
Hodgkin Lymphoma, Lymphocytic Leukemia, Mixed Cell Leukemia Trial run by the NCI (Stem cell transplantation)
Completed
- Hodgkin Lymphoma
- +8 more
- Stem cell transplantation
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 13, 2019
Myeloid Leukemias, AML, Leukemia Trial in Philadelphia (Rapamycin, Mitoxantrone, Etoposide, Cytarabine, Rapamycin + MEC)
Completed
- Myeloid Leukemias
- +3 more
- Rapamycin, Mitoxantrone, Etoposide, Cytarabine
- Rapamycin + MEC
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania Abramson Cancer Center
Jul 10, 2019
CML, Nilotinib, Imatinib Resistant Trial in Seoul (nilotinib)
Completed
- CML
- +3 more
-
Seoul, Korea, Republic ofSt. Mary hospital, Catholic medical center
Feb 24, 2017
CML, AML, MDS Trial in Philadelphia (Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells, Observation Arm)
Completed
- CML
- +6 more
- Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells
- Observation Arm
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Aug 17, 2016
Leukemia, AML, MDS Trial in Houston (Cytarabine, Fludarabine)
Completed
- Leukemia
- +3 more
-
Houston, TexasUT MD Anderson Cancer Center
Feb 17, 2016
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Blast-phase Chronic Myelogenous Leukemia Trial in Tampa, Baltimore, Durham
Completed
- Acute Myeloid Leukemia
- +5 more
- STA-9090 (ganetespib)
-
Tampa, Florida
- +2 more
Sep 17, 2014
AML, CML, MDS Trial in Boston, New York, San Antonio (STA-9090 (ganetespib))
Completed
- AML
- +3 more
- STA-9090 (ganetespib)
-
Boston, Massachusetts
- +2 more
Sep 17, 2014
Unrelated Stem Cell Transplantation for Hematopoietic Disorders
Completed
- CML
- +5 more
-
San Francisco, CaliforniaUniversity of California San Francisco
Aug 1, 2013
CML Trial in Petah tikva (Treatment modification based on molecular response at 3 months)
Unknown status
- CML
- Treatment modification based on molecular response at 3 months
-
Petah tikva, IsraelRabin Medical Center
Jan 7, 2013
AML, CML, MDS Trial in New York (CYT107 - Recombinant glycosylated human interleukin 7., rhIL-7 (CYT107))
Completed
- AML
- +2 more
- CYT107 - Recombinant glycosylated human interleukin 7.
- rhIL-7 (CYT107)
-
New York, New YorkMemorial Sloan-Kettering Cancer Institute
Jul 25, 2012
Hematologic Malignancy, AML, ALL Trial in Boston (CD+8 T cell depletion)
Completed
- Hematologic Malignancy
- +6 more
- CD+8 T cell depletion
-
Boston, Massachusetts
- +1 more
Mar 15, 2012
AML, MDS, ALL Trial in Seoul (fludarabine phosphate, busulfan)
Unknown status
- AML
- +4 more
- fludarabine phosphate, busulfan
-
Seoul, Korea, Republic ofDong Hwan Kim
Dec 29, 2008